New patent for Jazz Pharms drug XYREM
Annual Drug Patent Expirations for XYREM Xyrem is a drug marketed by Jazz Pharms and is included in one NDA. […]
Source
Annual Drug Patent Expirations for XYREM Xyrem is a drug marketed by Jazz Pharms and is included in one NDA. […]
Source
Annual Drug Patent Expirations for MOVANTIK Movantik is a drug marketed by Valinor and is included in one NDA. It […]
Source
Annual Drug Patent Expirations for RINVOQ Rinvoq is a drug marketed by Abbvie and is included in two NDAs. It […]
Source
Dabigatran etexilate mesylate is the generic ingredient in two branded drugs marketed by Alkem Labs Ltd, Apotex, Hetero Labs Ltd […]
Source
New tentative approval for Alembic drug dabigatran etexilate mesylate Read Post »
The fields of biotechnology and advanced drug delivery systems are rapidly converging, ushering in a new era of precision medicine
The landscape of cancer treatment is undergoing a dramatic transformation, driven by groundbreaking advances in biotechnology. From gene editing to
Biotechnology and Cancer: A Revolutionary Approach to Treatment Read Post »
Excipients, the inactive ingredients in pharmaceutical formulations, play a crucial role in drug manufacturing and delivery. While often overlooked, their quality and grade can significantly impact a drug product’s critical quality attributes, su…
Understanding Excipient Grades: What You Need to Know Read Post »
The fields of biotechnology and advanced drug delivery systems are rapidly converging, ushering in a new era of precision medicine
The Convergence of Biotechnology and Advanced Drug Delivery: Revolutionizing Medicine Read Post »
Annual Drug Patent Expirations for ZORYVE Zoryve is a drug marketed by Arcutis and is included in two NDAs. It is available from one supplier. There are seven patents protecting this drug. ZORYVE drug price trends. This drug has forty-two patent family…
Dabigatran etexilate mesylate is the generic ingredient in two branded drugs marketed by Alkem Labs Ltd, Apotex, Hetero Labs Ltd Iii, and Boehringer Ingelheim and, and is included in five NDAs. There are three patents protecting this compound. Drug pat…
New tentative approval for Alembic drug dabigatran etexilate mesylate Read Post »
Get new actionable insights and updates from BiotechBlog